直接作用抗病毒药物对丙型肝炎病毒感染患者生活质量的影响：一项荟萃分析。
The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis.
机构信息
The First Affiliated Hospital of Xi'an Medical University, Xi'an, China.
Xi'an Medical University, Xi'an, China.
出版信息
Ann Hepatol. 2022 Jul-Aug;27(4):100705. doi: 10.1016/j.aohep.2022.100705. Epub 2022 Apr 8.
INTRODUCTION AND OBJECTIVES
It is well known that the quality of life (QoL) of patients with chronic hepatitis C (HCV) is lower than that of the general population and that therapy with direct-acting antivirals (DAA) for HCV is safe and effective. However, data on the QoL of patients are scanty. The purpose of this study was to assess the effect of DAA drugs on patients' QoL.
METHODS
The literature included in this meta-analysis was due in March 2021. The random effect model of heterogeneous data and the fixed effect model of homogeneous data were used to analyze the data. QoL had to be evaluated using the Short Form Health Survey (SF-36) questionnaire with at least one measure at baseline (T0) and one measure at 12 weeks (T12) or 24 weeks (T24) after the end of therapy. The meta-analysis included eight studies, which involved 1,619 patients.
RESULTS
At T12, the meta-analysis showed all items of the SF-36 questionnaire improved from the pretreatment to post-treatment period and reached statistical significance (p < 0.05) except for the bodily pain (mean difference: 1.16, 95%CI -0.43-2.74) and role limitations-emotional (mean difference: 4.10, 95%CI -1.32-9.52). However, after subgroup analysis (whether ribavirin was being used or not), the bodily pain domain (mean difference: 3.34, 95%CI 1.03-5.65) became statistically significant again. At T24, the results indicated that all items of the SF-36 questionnaire improved from the pretreatment to the post-treatment period and reached statistical significance (p < 0.05) except for the role limitations-emotional domain (mean difference: 4.50, 95%CI -2.66-11.66).
CONCLUSIONS
There is evidence indicating that DAA therapy is accompanied by an improvement in QoL. Patients receiving DAA medication have a clinically relevant improvement in most domains of the SF-36 questionnaire at T12 or T24, except for a few aspects including role limitations-emotional.
简介和目的
众所周知，慢性丙型肝炎（HCV）患者的生活质量（QoL）低于一般人群，直接作用抗病毒药物（DAA）治疗 HCV 是安全有效的。然而，关于患者 QoL 的数据很少。本研究的目的是评估 DAA 药物对患者 QoL 的影响。
方法
本荟萃分析纳入的文献截止日期为 2021 年 3 月。使用异质数据的随机效应模型和同质数据的固定效应模型分析数据。QoL 必须使用健康调查简表（SF-36）进行评估，该问卷至少在基线（T0）时进行一次测量，并且在治疗结束后 12 周（T12）或 24 周（T24）时进行一次测量。荟萃分析纳入了 8 项研究，共涉及 1619 名患者。
结果
在 T12 时，荟萃分析显示 SF-36 问卷的所有项目均从治疗前到治疗后改善，并且达到统计学意义（p<0.05），除了身体疼痛（平均差异：1.16，95%CI-0.43-2.74）和情感角色限制（平均差异：4.10，95%CI-1.32-9.52）。然而，经过亚组分析（是否使用利巴韦林），身体疼痛域（平均差异：3.34，95%CI 1.03-5.65）再次具有统计学意义。在 T24 时，结果表明 SF-36 问卷的所有项目均从治疗前到治疗后改善，并且达到统计学意义（p<0.05），除了情感角色限制域（平均差异：4.50，95%CI-2.66-11.66）。
结论
有证据表明 DAA 治疗伴随着 QoL 的改善。接受 DAA 药物治疗的患者在 T12 或 T24 时在 SF-36 问卷的大多数领域都有临床相关的改善，除了少数方面，如情感角色限制。
Zotero 插件